← All trials
NCT07295223
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2025
- Primary completion
- Aug 31, 2026
- Completion date
- Sep 30, 2026
- First posted
- Dec 19, 2025
- Last posted
- Dec 19, 2025
- Enrollment
- 44
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Instituto Mexicano del Seguro SocialLead sponsor
- Instituto Mexicano del Seguro SocialSponsor investigator
- Universidad de GuanajuatoCollaborator
- Universidad de GuanajuatoOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.